Literature DB >> 10860767

Different regulation of cardiac and renal corticosteroid receptors in aldosterone-salt treated rats: effect of hypertension and glucocorticoids.

J S Silvestre1, V Robert, B Escoubet, C Heymes, A Oubénaïssa, C Desopper, B Swynghedauw, C Delcayre.   

Abstract

This study analysed the regulation of cardiac mineraloreceptor (MR) and glucoreceptor (GR) in aldosterone-salt treatment (AST). AST causes hypertension, left ventricle (LV) hypertrophy and decreases plasma corticosterone level. Ribonuclease protection assay and Western blot analysis showed a rise of MR mRNA (1.5- and 1.4-fold at day 15 and 30, respectively) and protein levels (1.8- and 4.1-fold at day 30 and 60, respectively) in the LV, but not in either the right ventricle (RV) or in kidney of treated rats. Addition of MR antagonist spironolactone (20 mg/kg/day) for 30 days failed to prevent these changes but was able to reduce AST-induced cardiac fibrosis. Similar hypertension-induced MR upregulations were observed in the LV of AngII-hypertensive rats and of 12-week-old SHR when compared to 4-week-old prehypertensive SHR. AST also enhanced left ventricular GR mRNA (2.0- and 3.0-fold at day 7 and 15, respectively) and protein contents (2.0- and 1.7-fold at day 30 and 60, respectively). In contrast to MR, GR levels were also upregulated in both RV and kidney. Such an upregulation was equally observed at mRNA and protein levels in LV, RV and kidney after adrenalectomy (15 days) and was prevented in both tissues after glucocorticoid replacement (adrenalectomy + dexamethasone at 100 micro g/kg/day for 15 days). Therefore, MR level may be controlled by hemodynamical factors whereas that of GR depends upon glucocorticoids level. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860767     DOI: 10.1006/jmcc.2000.1159

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  5 in total

1.  Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart.

Authors:  Celine Latouche; Yannis Sainte-Marie; Marja Steenman; Paulo Castro Chaves; Aniko Naray-Fejes-Toth; Geza Fejes-Toth; Nicolette Farman; Frederic Jaisser
Journal:  Endocrinology       Date:  2010-06-30       Impact factor: 4.736

2.  SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.

Authors:  Volker Vallon; Amanda W Wyatt; Karin Klingel; Dan Yang Huang; Azeemudeen Hussain; Susanne Berchtold; Björn Friedrich; Florian Grahammer; Rachida S Belaiba; Agnes Görlach; Peer Wulff; Jürgen Daut; Nancy D Dalton; John Ross; Ulrich Flögel; Jürgen Schrader; Hartmut Osswald; Reinhard Kandolf; Dietmar Kuhl; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-08       Impact factor: 4.599

3.  Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.

Authors:  Paula-Anahi Arias-Loza; Melanie Muehlfelder; Susan A Elmore; Robert Maronpot; Kai Hu; Hartmut Blode; Christa Hegele-Hartung; Karl Heinrich Fritzemeier; Georg Ertl; Theo Pelzer
Journal:  Toxicol Pathol       Date:  2009-12       Impact factor: 1.902

4.  Aldosterone-induced changes in the cardiac L-type Ca(2+) current can be prevented by antioxidants in vitro and are absent in rats on low salt diet.

Authors:  Michael Wagner; Elena Rudakova; Tilmann Volk
Journal:  Pflugers Arch       Date:  2008-05-27       Impact factor: 3.657

5.  Protective effects of spironolactone against hepatic ischemia/reperfusion injury in rats.

Authors:  Süleyman Atalay; Belkıs Soylu; Aslı Aykaç; Ayliz Velioğlu Öğünç; Şule Çetinel; Naziye Özkan; Can Erzik; Ahmet Özer Şehirli
Journal:  Turk J Surg       Date:  2019-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.